Stemgent, Pfizer Ink Research, Licensing Agreement For Research Reagents

Stemgent provides research tools and services to institutions, companies and universities in advancing in-vitro and in-vivo non-human stem cell research for research reagents.

According to the agreement, scientists involved in cell-based research will now be able to purchase fully licensed compounds with pharmaceutical modes of action as off-the-shelf products for use in non-clinical experiments.

Pfizer said that it is expected that along with other Stemgent offerings, the materials will benefit scientists working in a diverse range of stem cell and cell-based applications, including neuroscience, cancer and metabolic disease.

As part of the agreement, Pfizer and Stemgent are expected to form a joint research committee to review and evaluate the collaboration’s progress, coordinate results publication, monitor information and materials exchange between the two parties, nominate compounds and provide guidance relating to research tools for use in stem cell research.

Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine, said: “We are pleased to form this partnership with Stemgent. We all need research tools such as the molecules Stemgent can offer to dissect the pathways involved in stem cell biology and to advance our understanding of the science. I am delighted to join other industry and academic leaders on Stemgent’s Scientific advisory board.”

Ian Ratcliffe, president and CEO of Stemgent, said: “This is an important step for the scientific community as it increases our potential small molecule product offerings at a time when stem cell research gathers momentum and size around the world.”